Smith & Nephew New appointment & retirements of Non-Executive Directors

Medtech

Smith & Nephew Plc (LON:SN), the global medical technology business, has today announced the appointment of Rick Medlock as a Non-Executive Director.

Rick will join the Board and Audit Committee on 9 April 2020 at the conclusion of the Annual General Meeting. It is envisaged that Rick will replace Robin Freestone as Chair of the Audit Committee later in the year. Robin will remain on the Board in his capacity as Senior Independent Director.

Rick is a Non-Executive Director of Sophos plc, where he also chairs the Audit Committee and Risk Committee. He has more than 30 years’ experience of financial management in large international companies and was formerly Chief Financial Officer of Worldpay plc, Misys plc and Inmarsat plc.

Smith+Nephew also announces that Vinita Bali will be retiring as a Non-Executive Director at the end of 2020, on completion of 6 years’ service, and that Baroness Virginia Bottomley will also be retiring as a Non-Executive Director at the Annual General Meeting in April 2021, following completion of 9 years’ service.

Roberto Quarta, Chair of Smith+Nephew, said:

“I am delighted to welcome Rick Medlock to the Smith+Nephew Board. His extensive experience in both executive and non-executive finance leadership roles in global companies will strengthen our team. 

“I would also like to take the opportunity of thanking both Vinita and Virginia for their outstanding service to the Company. We look forward to their continuing contribution to the work of the Board over the coming months.”

Share on:

Latest Company News

Smith & Nephew to host Capital Markets Days in London and New York

Smith & Nephew will hold Capital Markets Days on 8 December in London and 11 December in New York to outline its new strategy, mid-term priorities, and portfolio growth plans.

Smith & Nephew Plc delivers strong H1 with profit up 31%

Smith+Nephew reported 5.0% underlying revenue growth and a 30.6% rise in operating profit for H1 2025. EPS rose 36.6% to 33.5¢ and free cash flow surged to $244m. The company also announced a $500m share buyback for H2, supported by strong cash generation and margin expansion.

Smith & Nephew appoints David King as Non-Executive Director

Smith & Nephew Plc announces the addition of David King as an independent Non-Executive Director, effective July 1, 2025, enhancing their healthcare leadership.

Smith & Nephew Plc 12-Point Plan increasingly delivering better financial performance

Smith & Nephew reports strong financial results for 2024 with significant revenue and profit growth, driven by innovation and strategic restructuring.

Smith & Nephew Plc delivers Q3 revenue of $1,412 million, 4% growth

Smith & Nephew's Q3 2024 update shows a 4% revenue growth to $1,412M. Despite China headwinds, US Orthopaedics and Sports Medicine excelled.

Smith & Nephew Plc transforming into a higher growth and more profitable business

Smith & Nephew plc (LON:SN, NYSE:SNN) reports a robust financial performance for Q2 and H1 2024, showing significant revenue and profit growth.

    Search

    Search